PR92163

LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire=KYODO JBN/ --

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical

company, and Dexa Medica, a leading Indonesian pharmaceutical company, today

announced the Indonesian launch of triptorelin for the treatment of women with

gynecological disorders, particularly endometriosis. Triptorelin, marketed

under the brand name Pamorelin(R) is one of the most common

gonadotropin-releasing hormone agonists (GnRH-a) used worldwide to help women

with endometriosis reduce pain-related symptoms by inducing a low estrogen

status. Clinical research revealed pain symptom improvement with Pamorelin(R)

as being confirmed by the reduction in the volume of endometriotic nodules

during treatment vs. placebo.[1]

Endometriosis is a chronic, debilitating disease involving long-term

inflammation and the presence of functional endometrial glands and stroma

outside the uterine cavity. Having serious consequences for general and

reproductive health, pelvic endometriosis has a high incidence estimated

between 10% of reproductive aged women worldwide (approximately 190 million)

and remains underdiagnosed.[2]  Furthermore, up to 49% of women reporting

chronic pelvic pain are known to suffer from endometriosis.[2] Dexa Medica's

nation-wide launch and distribution of triptorelin, as Debiopharm's exclusive

Indonesian licensee, will help patients in the region gain access to the

pain-relieving benefits of hormone suppression with Pamorelin(R).

"We naturally recognized that Dexa Medica was the ideal company to pioneer

triptorelin access to patients in Indonesia. Their high standards of ethics,

regional pharmaceutical leadership, and strong commercialization track record

and reputation align well with Debiopharm's values," stated Fabrice Paradies,

Senior Director, Business Development & Global Commercial Alliances,

Debiopharm. "This alliance with Dexa Medica is highly valued as they are

dedicated to covering Indonesia, with over 270 million people the largest

country in Southeast Asia, having the capability to manage the logistic

complexity to provide treatment access to patients in a country having a

population of over 270 million on nearly 1,000 inhabited islands."

"Medical management of endometriosis primarily aims to delay disease

progression and alleviate symptoms. Aside from infertility, the most

debilitating symptoms in women with endometriosis are pain manifested as severe

dysmenorrhea, dyspareunia, chronic pelvic pain, dysuria or dyschezia.  These

symptoms also tend to worsen with repeated menstrual cycles," stated Raymond R.

Tjandrawinata, Ph.D., Director of Business and Scientific Development PT Dexa

Medica.

"We, as a leading pharmaceutical company in Indonesia, are very proud and

excited to collaborate with a globally reputed company, Debiopharm, to market

quality products such as Triptorelin which helps Indonesians to overcome health

problems related to endometriosis. Although there is currently no definitive

data, the general prevalence is around 3% - 10%, especially in women of

reproductive age in Indonesia," stated Commercial Director PT Dexa Medica, V

Hery Sutanto.

About Pamorelin(R)

Pamorelin(R) (triptorelin) is an agonist analogue of the natural

gonadotropin-releasing hormone (GnRH), the only agonist of its kind that

differs from natural GnRH by a single amino acid and works by decreasing the

amount of certain hormones in the body. Pamorelin(R) helps women to maintain

estradiol suppression, an important factor in the management and relief of

chronic pain associated with endometriosis. When the basic activation process

of the GnRH receptor is interrupted, this initiates a cascade of events leading

to the fall in pituitary luteinizing hormone (LH) and follicle stimulating

hormone (FSH) secretion, causing a low production of circulating estradiol and

progesterone. Manufactured by Debiopharm in Switzerland, this long-acting

formulation is marketed and distributed globally through regional licensees.

About Dexa Medica

PT Dexa Medica (member of Dexa Group) is a leading Indonesian research-based

pharmaceutical company, which was established on September 27th, 1969. Starting

with the export of pharmaceutical products created by Indonesian scientists in

1993, now Dexa Medica has exported pharmaceutical products to 4 continents:

Africa, America, Asia and Europe. Regarding the export of pharmaceutical

products, Dexa Medica has become a pioneer in Indonesian pharmaceutical

manufacturers entering the UK and was awarded the Primaniyarta Award from the

Indonesian government in 2017, 2018, and 2019.

Debiopharm's commitment to patients

Debiopharm aims to develop & manufacture innovative therapies that target high

unmet medical needs in oncology and infectious diseases. Bridging the gap

between disruptive discovery products and real-world patient reach, we identify

high-potential compounds and technologies for in-licensing, clinically

demonstrate their safety and efficacy and then select large pharmaceutical

commercialization partners to maximize patient access globally.

For more information, please visit www.debiopharm.com  

We are on Twitter. Follow us @DebiopharmNews at

http://twitter.com/DebiopharmNews  

Debiopharm Contact

Dawn Haughton

Communication Manager  

dawn.bonine@debiopharm.com

Tel: +41 (0)21 321 01 11

Dexa Medica Contact

Sonny Himawan

Head of Corporate Communications

soni.himawan@dexagroup.com

References:

1.  Maggiore ULR et al. Expert Opin Pharmacother 2014 Jun;15(8):1153-79.

2.  Zondervan K et al. N Engl J Med 2020;382:1244-1256

Source: Debiopharm International SA